[en] Objective: Avocado/soybean unsaponifiables (ASUs) are commonly used to treat OA symptoms. However, there are many ASU mixtures on the market with differing compositions and pharmacological activities. This study aimed to compare the composition and pharmacological activity of seven commercially available ASU products on human osteoarthritis chondrocytes. Methods: The contents of the lipidic part of ASUs were characterized by gas chromatography analysis using a VARIAN 3400 chromatograph. The pharmacological activity of the ASU products was tested on human osteoarthritis chondrocytes cultured in alginate beads. Their effects were evaluated on aggrecan, interleukin (IL)-6 and -8, and matrix metalloproteases (MMP)-3 using immunoassays and on nitric oxide through measurement of nitrite via spectrometry. Results: PIASCLEDINE-ExpASU® showed a specific profile with the presence of chromatographic peaks corresponding to an alkyl furan fraction and alkyl triols. PIASCLEDINE-ExpASU®, Persemax, Insaponifiable 300, Arthrocen, and Arthocare contained quantifiable amounts of tocopherol, while tocopherol was undetectable in Avovida and Saponic. Squalene was found only in PIASCLEDINE-ExpASU®. The abundance of sterols varied depending on the product. PIASCLEDINE-ExpASU® was the most active of the tested ASU products in inhibiting nitric oxide, IL-6, and IL-8 production by chondrocytes. With the exception of Saponic and Persemax, all the ASU mixtures either slightly or significantly increased aggrecan production. MMP-3 levels were significantly decreased by Insaponifiable 300 and PIASCLEDINE-ExpASU® and significantly increased by Saponic. Conclusion: The composition of PIASCLEDINE-ExpASU® is different to that of the other evaluated ASU mixtures. This specific composition explains its better pharmacological activity, including the higher inhibitory effect on pro-inflammatory and pro-catabolic factors. Our findings are helpful in providing a basis for understanding the symptomatic effect of PIASCLEDINE-ExpASU® in patients with osteoarthritis.
Disciplines :
Rheumatology
Author, co-author :
Lambert, Cécile ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)
Bellemère, Gaëlle; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Boyer, Gaëtan; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Ponelle, Frank; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Bauer, Thierry; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Legeny, Marie-Christine; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Baudouin, Caroline; Innovation, Research and Development, Laboratoires Expanscience, Epernon, France
Henrotin, Yves ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM) ; Department of Physical Therapy and Rehabilitation, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium ; Artialis S.A., Liège, Belgium
Language :
English
Title :
Composition Analysis and Pharmacological Activity of Avocado/Soybean Unsaponifiable Products Used in the Treatment of Osteoarthritis.
Abubakar A. R. Haque M. (2020). Preparation of Medicinal Plants: Basic Extraction and Fractionation Procedures for Experimental Purposes. J. Pharm. Bioallied Sci. 12, 1–10. Available at: /pmc/articles/PMC7398001/ (Accessed August 31, 2021). 10.4103/jpbs.JPBS_175_19
Anon (2021a). Efficacy and Safety of Avocado/soybean Unsaponifiables in the Treatment of Symptomatic Osteoarthritis of the Knee and Hip. A Prospective, Multicenter, Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial - PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/9476272/ (Accessed May 3, 2021).
Anon (2021b). Recommendations For the Medical Management of Osteoarthritis of the Hip and Knee: 2000 Update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines - PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/11014340/ (Accessed September 6, 2021).
Appelboom T. Schuermans J. Verbruggen G. Henrotin Y. Reginster J. Y. (2001). Symptoms Modifying Effect of Avocado/soybean Unsaponifiables (ASU) in Knee Osteoarthritis. A Double Blind, Prospective, Placebo-Controlled Study. Scand. J. Rheumatol. 30, 242–247. Available at: https://pubmed.ncbi.nlm.nih.gov/11578021/ (Accessed May 3, 2021). 10.1080/030097401316909602
Brown B. I. (1973). Qualitative and Quantitative Estimation by Thin-Layer and Gas Chromatography of a Series of C17 Oxygenated Aliphatic Compounds in the Avocado (Persea Americana). J. Chromatogr. A 86, 239–245. 10.1016/s0021-9673(01)81264-4
Edgard Henrotin Y. (2018). Avocado/Soybean Unsaponifiables (Piacledine300) Show Beneficial Effect on the Metabolism of Osteoarthritic Cartilage, Synovium and Subchondral Bone: An Overview of the Mechanisms. AIMS Med. Sci. 5, 33–52. Available at: http://www.aimspress.com/article/doi/10.3934/medsci.2018.1.33 (Accessed May 3, 2021). 10.3934/medsci.2018.1.33
Farines M. Soulier J. Rancurel A. Montaudoin M. G. Leborgne L. (1995). Influence of Avocado Oil Processing on the Nature of Some Unsaponifiable Constituents. J. Am. Oil Chem. Soc. 72, 473–476. Available at: https://link.springer.com/article/10.1007/BF02636092 (Accessed August 31, 2021). 10.1007/bf02636092
Ghasemian M. Owlia S. Owlia M. B. (2016). Review of Anti-inflammatory Herbal Medicines. Adv. Pharmacol. Sci. 2016, 9130979. Available at: https://pubmed.ncbi.nlm.nih.gov/27247570/ (Accessed April 23, 2021). 10.1155/2016/9130979
Glyn-Jones S. Palmer A. J. R. Agricola R. Price A. J. Vincent T. L. Weinans H. et al. (2015). “Osteoarthritis,”in The Lancet, 386 9991), 376–387. Epub of Print. 10.1016/s0140-6736(14)60802-3
Honvo G. Reginster J. Y. Rabenda V. Geerinck A. Mkinsi O. Charles A. et al. (2019). Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging 36, 65–99. Available at: /pmc/articles/PMC6509099/ (Accessed April 23, 2021). 10.1007/s40266-019-00662-z
Hunter D. J. March L. Chew M. (2020). Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet 396, 1711–1712. Available at: https://pubmed.ncbi.nlm.nih.gov/33159851/ (Accessed September 6, 2021). 10.1016/S0140-6736(20)32230-3
Jordan K. M. Arden N. K. Doherty M. Bannwarth B. Bijlsma J. W. Dieppe P. et al. (2003). EULAR Recommendations 2003: an Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62, 1145–1155. Available at: https://pubmed.ncbi.nlm.nih.gov/14644851/ (Accessed September 6, 2021). 10.1136/ard.2003.011742
Karel P. Coste P. Géher P. Krejci G. (2010). Efficacy and Safety of Piascledine 300 versus Chondroitin Sulfate in a 6 Months Treatment Plus 2 Months Observation in Patients with Osteoarthritis of the Knee. Clin. Rheumatol. 29, 659–670. Available at: https://pubmed.ncbi.nlm.nih.gov/20179981/(Accessed May 3, 2021).
Kashman Y. Néeman I. Lifshitz A. (1969). New Compounds from Avocado Pear. Tetrahedron 25, 4617–4631. 10.1016/s0040-4020(01)83005-2
Labarca C. Paigen K. (1980). A Simple, Rapid, and Sensitive DNA Assay Procedure. Anal. Biochem. 102, 344–352. Available at: https://pubmed.ncbi.nlm.nih.gov/6158890/ (Accessed April 23, 2021). 10.1016/0003-2697(80)90165-7
Lambert C. Zappia J. Sanchez C. Florin A. Dubuc J.-E. Henrotin Y. (2021). The Damage-Associated Molecular Patterns (DAMPs) as Potential Targets to Treat Osteoarthritis: Perspectives from a Review of the Literature. Front. Med. 7, 607186. 10.3389/fmed.2020.607186
Lippiello L. Nardo J. V. Harlan R. Chiou T. (2008). Metabolic Effects of Avocado/soy Unsaponifiables on Articular Chondrocytes. Evidence-Based Complement. Altern. Med., 5, 191–197. Available at: https://pubmed.ncbi.nlm.nih.gov/18604259/ (Accessed September 6, 2021). 10.1093/ecam/nem132
Loeser R. F. Goldring S. R. Scanzello C. R. Goldring M. B. (2012). Osteoarthritis: a Disease of the Joint as an Organ. Arthritis Rheum. 64, 1697–1707. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22392533. 10.1002/art.34453
Maheu E. Cadet C. Marty M. Moyse D. Kerloch I. Coste P. et al. (2014). Randomised, Controlled Trial of Avocado-Soybean Unsaponifiable (Piascledine) Effect on Structure Modification in Hip Osteoarthritis: The ERADIAS Study. Ann. Rheum. Dis. 73, 376–384. Available at: https://pubmed.ncbi.nlm.nih.gov/23345601/ (Accessed April 23, 2021). 10.1136/annrheumdis-2012-202485
Maheu E. Mazières B. Valat J. P. Loyau G. Le Loët X. Bourgeois P. et al. (1998). Symptomatic Efficacy of Avocado/soybean Unsaponifiables in the Treatment of Osteoarthritis of the Knee and Hip: a Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial with a Six-Month Treatment Period and a Two-Month Followup Demonstrating a Persistent Effect. Arthritis Rheum. 41, 81–91. Available at: https://pubmed.ncbi.nlm.nih.gov/9433873/ (Accessed May 3, 2021). 10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9
Mathy-Hartert M. Jacquemond-Collet I. Priem F. Sanchez C. Lambert C. Henrotin Y. (2009). Curcumin Inhibits Pro-inflammatory Mediators and Metalloproteinase-3 Production by Chondrocytes. Inflamm. Res. 58, 899–908. Available at: https://pubmed.ncbi.nlm.nih.gov/19579007/ (Accessed April 23, 2021). 10.1007/s00011-009-0063-1
Msika P. Baudouin C. Saunois A. Bauer T. (2008). Avocado/soybean Unsaponifiables, ASU EXPANSCIENCE, Are Strictly Different from the Nutraceutical Products Claiming ASU Appellation. Osteoarthritis Cartilage 16, 1275–1276. Available at: https://pubmed.ncbi.nlm.nih.gov/18420430/ (Accessed September 6, 2021). 10.1016/j.joca.2008.02.017
Néeman I. Lifshitz A. Kashman Y. (1970). New Antibacterial Agent Isolated from the Avocado Pear. Appl. Microbiol. 19, 470–473. Available at: https://pubmed.ncbi.nlm.nih.gov/4985830/ (Accessed August 31, 2021). 10.1128/am.19.3.470-473.1970
Rahmati M. Mobasheri A. Mozafari M. (2016). Inflammatory Mediators in Osteoarthritis: A Critical Review of the State-Of-The-Art, Current Prospects, and Future Challenges. Bone 85, 81–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26812612. 10.1016/j.bone.2016.01.019
Sanchez C. Mateus M. M. Defresne M. P. Crielaard J. M. Reginster J. Y. Henrotin Y. E. (2002). Metabolism of Human Articular Chondrocytes Cultured in Alginate Beads. Longterm Effects of Interleukin 1beta and Nonsteroidal Antiinflammatory Drugs. J. Rheumatol. 29, 772–782. Available at: https://pubmed.ncbi.nlm.nih.gov/11950021/ (Accessed April 23, 2021).
Swain S. Sarmanova A. Coupland C. Doherty M. Zhang W. (2020). Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res. (Hoboken) 72, 991–1000. Available at: https://pubmed.ncbi.nlm.nih.gov/31207113/ (Accessed September 6, 2021). 10.1002/acr.24008
Vos T. Abajobir A. A. Abbafati C. Abbas K. M. Abate K. H. Abd-Allah F. et al. (2017). Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259. Available at: https://pubmed.ncbi.nlm.nih.gov/28919117/ (Accessed May 3, 2021) 10.1016/S0140-6736(18)32279-7
Zhang W. Doherty M. Arden N. Bannwarth B. Bijlsma J. Gunther K. P. et al. (2005). EULAR Evidence Based Recommendations for the Management of Hip Osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 64, 669–681. Available at: /pmc/articles/PMC1755499/ (Accessed September 6, 2021). 10.1136/ard.2004.028886
